peptidylprolyl isomerase A pseudogene 39Genealiases: []
Q-omics provides the consensus-scored PPIAP39 profile across patient tissues and cancer cell-line models. PPIAP39 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in LUAD. Among the 18 cancer types available for tumor–normal comparison, PPIAP39 is differentially expressed in 13, with the highest sampling consensus in THCA. Additionally, PPIAP39 RNA expression shows 11,626 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight LUAD, THCA, and TGCT as cancer lineages where PPIAP39 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PPIAP39 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PPIAP39 survival associations across molecular data types. PPIAP39 RNA expression shows survival associations in the most cancer types (24). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PPIAP39 RNA expression–survival associations across cancer types. High PPIAP39 expression shows unfavorable associations in KIRP, GBM and KIRC, but favorable associations in LUAD, CESC and THCA. The LUAD Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify LUAD as the clearest survival context for PPIAP39 RNA expression.
This table summarizes PPIAP39 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for PPIAP39. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PPIAP39 shows lower tumor expression in THCA, BRCA, LUAD, BLCA, LUSC and UCEC. The THCA box plot shows higher PPIAP39 RNA expression in normal versus tumor tissue (log2 FC = −2.026, t-test p < 0.001).
This table shows molecular features associated with PPIAP39 in patient tissues and cancer cell lines. In patient samples, PPIAP39 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set.
